DexCom is trading 4.1% up at $86.85 as investors digest record margin expansion and a strategic pivot toward the large Type 2 diabetes market.
- The move extends a sharp rally following the company's late-July earnings release and guidance raise.
- The stock previously jumped 11.95% on July 31, rising from $74.54 to $83.45, signaling sustained bullish sentiment following the updated outlook.